1. Is high salt intake inducing obesity via production of cortisol? A novel working hypothesis and pilot study.
- Author
-
Nowell, Anthony, Torres, Susan J., Hall, Sarah J., Keske, Michelle A., Torpy, David J., Parker, Lewan, Betik, Andrew C., and Turner, Anne I.
- Subjects
- *
SALIVA analysis , *RESEARCH funding , *DATA analysis , *T-test (Statistics) , *PILOT projects , *FISHER exact test , *HYDROCORTISONE , *TREATMENT duration , *TIME series analysis , *DESCRIPTIVE statistics , *DIETARY sodium , *CROSSOVER trials , *HYPOTHESIS , *ADRENOCORTICOTROPIC hormone , *ANALYSIS of variance , *STATISTICS , *SODIUM , *ANTHROPOMETRY , *DATA analysis software , *OBESITY , *NONPARAMETRIC statistics - Abstract
Purpose: Evidence is growing that high salt intake is an independent risk factor for obesity, but the mechanisms are unknown. Our novel working hypothesis is that high salt intake drives cortisol production, which in turn, drives obesity. The current study aimed to demonstrate an acute cortisol response following a single high salt meal. Methods: Eight participants (age 30.5 ± 9.8 years [mean ± SD], 50% female), consumed high salt (3.82 g; 1529 mg sodium) and low salt (0.02 g; 9 mg sodium) meals in a randomized cross-over design. Results: Urinary and salivary cortisol and plasma adrenocorticotropic hormone (ACTH) demonstrated order effects. When high salt was given second, there was a peak above baseline for urinary cortisol (26.3%), salivary cortisol (9.4%) and plasma ACTH (4.1%) followed by a significant decline in each hormone (treatment*time, F[9, 18] = 2.641, p = 0.038, partial η2 = 0.569; treatment*time, F[12, 24] = 2.668, p = 0.020, partial η2 = 0.572; treatment*time, F[12, 24] = 2.580, p = 0.023, partial η2 = 0.563, respectively), but not when high salt was given first (p > 0.05 for all). Conclusion : These intriguing findings provide partial support for our hypothesis and support a need for further research to elucidate the role of high salt intake in cortisol production and, in turn, in the aetiology of obesity. Trial registration number: ACTRN12623000490673; date of registration 12/05/2023; retrospectively registered. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF